Open AccessMethotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV
Author(s) -
David Gingrich,
Amelia N. Deitchman,
Amy Kantor,
Liusheng Huang,
James H. Stein,
Judith S. Currier,
Priscilla Y. Hsue,
Heather J. Ribaudo,
Francesca Aweeka,
Actg Protocol Team
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002502
Subject(s) - placebo , medicine , cmax , dosing , cmin , clinical endpoint , regimen , pharmacokinetics , methotrexate , randomized controlled trial , pharmacology , alternative medicine , pathology
To mitigate increased risk of premature cardiovascular disease in antiretroviral therapy (ART) suppressed adults living with HIV (PWH), low-dose methotrexate (LDMTX) was evaluated in a multicenter randomized placebo controlled clinical trial of 176 PWH taking various ART regimens (ACTG A5314). Given shared methotrexate (MTX) and tenofovir (TFV) pharmacokinetic (PK) pathways, a substudy was conducted to investigate whether LDMTX alters TFV exposure.